SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the subject of intense retail speculation, with traders debating whether its recent price action represents a speculative bubble or a long-term opportunity, leading to volatile swings and high trading volume. The community is sharply divided, with some investors aggressively buying dips in anticipation of future index inclusion while others are betting on a significant correction, labeling it an overhyped IPO.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh conflicting visions for the company's future, with ongoing boardroom drama and proxy fighting clashing with community speculation regarding potential data center tenant deals. Market participants are intensely focused on unusual options activity and the strategic value of the firm's energy-infrastructure-heavy land holdings in Texas.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as a significant short interest faces potential pressure following strong Phase 3 clinical data for its gene-editing candidate. The community is actively debating the likelihood of a major pharmaceutical buyout and the implications of recent capital raising activities on the stock's future trajectory.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor a high-stakes legal dispute with its partner, Nippon Shinyaku, ahead of a crucial August FDA decision for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively debating the impact of this litigation on commercialization rights while expressing optimism that strong clinical trial data will ultimately drive an approval and significant upside.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors debate its valuation and potential for a short squeeze, while also expressing significant frustration with management's communication and the stock's prolonged underperformance. The conversation is heavily focused on the company's rare disease gene therapy pipeline, the impact of recent clinical trial data, and speculation regarding a potential buyout.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is seeing massive volatility after the FDA rejected its Phase I/II data for its Huntington's disease gene therapy, mandating a new, randomized, sham-controlled trial instead of the expected accelerated approval path. The community is sharply divided, with frustrated investors debating the ethics of sham surgeries on terminal patients, while many are now bracing for significant delays and potential cash-burn concerns despite the company's existing capital runway.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing significant momentum driven by growing interest in post-quantum cryptography (PQC) and the firm's strategic partnerships with major tech giants, which has intensified speculative interest from retail investors. Community discussions are heavily focused on a potential short squeeze due to the stock's low float and high institutional ownership, with many traders drawing parallels to other parabolic moves in the quantum computing sector.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is attracting significant attention as investors anticipate a potential short squeeze, fueled by high short interest and anticipation for the upcoming first-quarter earnings report. Community sentiment remains bullish, with many focusing on the company's strong fundamentals and perceived growth potential as a fintech super app, despite broader market volatility and recent board-level governance changes.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on the company's confirmed single-trial pathway for AXPAXLI, with community discourse centered on the Q4 2026 NDA submission timeline and potential for future acquisition by major pharmaceutical players. While some investors express optimism regarding the regulatory de-risking event, others remain cautious, debating the long-term competitive impact of the data and the significance of recent trading volatility.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently drawing significant investor interest as the community weighs a combination of aggressive share buybacks, steady dividends, and a potential pivot toward a data-driven model following recent network expansion. While some participants express frustration over ongoing broadband subscriber losses and intense competition, others are aggressively averaging down, viewing the stock as a deeply undervalued play ahead of upcoming earnings and seasonal catalysts like the World Cup.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
